Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma (IPHA) reported first-half 2026 results and a new global partnership with Sobi for lacutamab, including a USD 75 million upfront payment following transaction closing on September 16, 2026.
The Sobi deal supports initiation of the TELLOMAK-3 Phase 3 CTCL study, with first patient expected in Q1 2027, and could bring up to USD 505 million in additional milestones plus tiered double-digit royalties. Innate also completed a €30 million private placement of 17,647,059 new shares and expects, together with the Sobi upfront payment, to extend its cash runway to the end of Q1 2028. As of June 30, 2026, cash, cash equivalents, short-term investments and financial assets were €21.4 million and financial liabilities were €20.2 million. Revenue and other income reached €5.7 million, while operating expenses fell to €24.7 million, driven by lower R&D and G&A costs.
Innate Pharma (IPHA) reports that its previously announced strategic partnership with Sobi is now effective after antitrust waiting periods expired and other closing conditions were met.
Completion of the transaction triggers a USD 75 million upfront payment to Innate and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, with first patient enrollment expected in Q1 2027. Under the agreement, Innate will conduct the TELLOMAK-3 trial, which is intended to support applications for full approvals in Sézary syndrome and mycosis fungoides in key jurisdictions. Sobi receives exclusive global commercialization rights to lacutamab upon potential accelerated approval and may assume full global development rights following positive Phase 3 results.
Innate Pharma (IPHA) will host a conference call and webcast on September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT to present its first half 2026 business update.
The call will feature CEO Jonathan Dickinson, Chief Medical Officer Markus Jensen, Chief Operating Officer Yannis Morel and Chief Financial Officer Frédéric Lombard. Access links for the webcast and conference call are provided in the Investors section of Innate Pharma’s website. A replay of the webcast will be available on the company website for 90 days after the event.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, from September 14–16, 2026. Members of the executive team will join a fireside chat and hold one-on-one investor meetings.
The fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast accessible via the Events page of the Investors section on Innate Pharma’s website and a replay available afterward. According to the company, Innate is a clinical-stage biotechnology group focused on next‑generation antibody therapeutics, including its proprietary ADC pipeline led by IPH4502 and partnered late‑stage assets lacutamab and monalizumab.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call and live webcast on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The call will feature CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations & Communications Stéphanie Cornen.
The live webcast can be accessed via Q4 links provided by the company and through the Investors section of Innate Pharma’s website, where a replay will also be available. Innate Pharma is a clinical-stage biotechnology company focused on immuno-oncology and antibody-drug conjugates, including its lead Nectin-4 ADC IPH4502 and partnered late-stage assets lacutamab with Sobi and monalizumab with AstraZeneca.
Innate Pharma (Euronext Paris: IPH, Nasdaq: IPHA) plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T‑cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome. This advancement is subject to closing of its strategic partnership with Sobi, including required anti‑trust clearance.
According to Innate, the agreement’s USD 75 million upfront payment, payable at closing, and near‑term milestones tied to Sézary syndrome are expected to fund TELLOMAK-3 execution and regulatory filings and extend the company’s cash runway through Q3 2027. Innate also appointed Markus Jensen as Chief Medical Officer and Executive Leadership Team member, effective September 1, 2026, succeeding Sonia Quaratino. Lacutamab holds multiple U.S. and EU regulatory designations and is progressing toward an open‑label, multicenter, randomized Phase 3 trial in Sézary syndrome and mycosis fungoides.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) entered a strategic partnership with Sobi to advance lacutamab in cutaneous T‑cell lymphoma (CTCL), enabling initiation of the confirmatory TELLOMAK‑3 Phase 3 study. The trial is designed to support a planned accelerated approval filing in Sézary syndrome and later full approvals in Sézary syndrome and mycosis fungoides.
According to Innate Pharma, Sobi will pay USD 75 million at closing and Innate may receive up to USD 40 million in near‑term Sézary‑linked milestones and up to USD 465 million tied to Sobi’s option for full development rights and future regulatory and commercial milestones, plus tiered double‑digit royalties on net sales. Sobi will receive exclusive global commercialization rights upon potential accelerated approval and may assume full global development rights following positive Phase 3 results, subject to closing conditions including antitrust clearance.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced that EVP Chief Medical Officer Sonia Quaratino will join the bladder cancer panel “Changing Treatment Landscape in Bladder Cancer” at the BTIG Virtual Biotechnology Conference 2026 on July 28, 2026, at 10:30 a.m. EDT / 4:30 p.m. CEST.
Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies, including IPH4502 (Nectin4 ADC in solid tumors), lacutamab (anti-KIR3DL2 in cutaneous T cell lymphomas) and monalizumab (anti-NKG2A in NSCLC, in collaboration with AstraZeneca). The company collaborates with partners such as Sanofi and AstraZeneca and is headquartered in Marseille, France.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) has completed enrollment in the dose-escalation part of its Phase 1 IPH4502-101 study (NCT06781983), evaluating IPH4502, a proprietary Nectin-4 exatecan antibody-drug conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.
The open-label, multi-center trial has recruited 76 patients in France and the United States. According to Innate Pharma, IPH4502 has shown a favorable safety profile to date, with limited hematological toxicity, consistent with the company’s hypothesis that its proprietary stable linker enables slow release of free exatecan. Preliminary anti-tumor activity has been observed, including objective responses in heavily pre-treated urothelial carcinoma patients previously treated with enfortumab vedotin, as well as in non-small cell lung cancer and head and neck squamous cell carcinoma. A preliminary data readout from the 76-patient dose-escalation cohort is expected by year-end to guide dose optimization and selection of tumor types for further development.
Innate Pharma (Nasdaq: IPHA) reported the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille.
According to Innate Pharma, shareholders cast 94 votes out of 34,872,293 shares representing 34,921,313 voting rights, for a stated quorum of 37,136%. AGM documentation and the meeting recording will be available on the company’s website.